Clinical Trials Logo

Toxemia clinical trials

View clinical trials related to Toxemia.

Filter by:

NCT ID: NCT06002295 Completed - Neonatal Sepsis Clinical Trials

A Comparative Analysis of 4% Chlorhexidine Versus Methylated Spirit as Prophylaxis of Omphalitis and Sepsis in Newborns

Start date: September 12, 2020
Phase: Phase 2
Study type: Interventional

Introduction: Neonatal sepsis in one of the leading cause of death in developing countries. Umbilical cord care is important as it may lead to infection. Topical treatment can help to reduce the chances of infection as well as increase the chances of early removal. In this regard methylated spirit and chlorhexidine are found to be effective. Aims and Objectives: To compare the effectiveness of 4% chlorhexidine and methylated spirit in newborns for prevention of omphalitis and neonatal sepsis. Materials and Methods: This randomized control trial was carried out in neonatal unit of Shaikh Zayed Hospital Lahore. After meeting the inclusion criteria, 300 neonates were enrolled. In group A 4% chlorhexidine was applied for cord care and in group B methylated spirit was used. Neonates were followed till 10th day of life. Careful examination was done for cord separation and for any signs of omphalitis or sepsis. If the neonate had no signs and symptoms of omphalitis and sepsis on 10th day of follow up then it was treatment success.

NCT ID: NCT05999682 Completed - Sepsis Clinical Trials

Improvement of Organ Function by Apigenin in Elderly Patients With Sepsis

Start date: September 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

In this single-center, randomized, single-blind, placebo-controlled pilot clinical trial. The effect of apigenin on the improvement of organ function will be investigated in elderly patients with sepsis. Researchers will screen patients admitted to the Department of Critical Care Medicine at Zhujiang Hospital to identify patients with sepsis based on including and excluding criteria and obtain informed consent and randomize them into groups. The treatment group will be given apigenin tablets 50mg ground with 5ml of sterilized water for intra-gastric tube injection; the control group will be given an equal volume of sterilized water for intra-gastric tube injection. The changes in SOFA score and other clinically meaningful outcomes in 4 days will be collected.

NCT ID: NCT05969327 Completed - Clinical trials for Importance of Vitamin D Therapy in Treatment of Neonatal Sepsis

Role of Vitamin D Therapy in Recovery From Early Neonatal Sepsis (Randomized Controlled Trial)

Start date: August 14, 2018
Phase: Phase 3
Study type: Interventional

Neonatal sepsis is still a major cause of morbidity and mortality despite major advances in neonatal intensive care units. Early-onset sepsis (EOS) is an infection of the blood acquired vertically from the mother and manifests shortly after birth. The objective of this study is to assess the vitamin D status in neonates with Early onset sepsis (EOS) and evaluate the influence of different doses of vitamin D3 (800 IU/d versus 400 IU/d), in these infants.

NCT ID: NCT05968287 Completed - Sepsis Clinical Trials

Can Measurement of Neutrophil-derived ROS Production be a Novel Biomarker of Sepsis?

LIT-sepsis
Start date: June 28, 2022
Phase:
Study type: Observational

Neutrophils are indispensable for host defense and have an important roles in modulating the immune system in both the innate and adaptive immune response. Neutrophils operate using a number of different mechanisms including chemotaxis, phagocytosis, release of reactive oxygen species (ROS) and granular proteins, and the production and liberation of cytokines for this purpose. A controlled neutrophil response is required to combat infection; an dysregulated state of this response can cause sepsis, tissue damage, and organ failure. Sepsis and septic shock are the leading causes of death especially in intensive care units (ICU), and their mortality can be reduced with prompt diagnosis and appropriate treatment modality. From this point of view, many biomarkers have been evaluated for the diagnosis, prognosis, and treatment response of infection and sepsis. An objective marker of cellular dysfunction of neutrophils would be a helpful tool for the clinician in detecting and monitoring changes related to infection status and to determine development of sepsis and positive effects of interventions.

NCT ID: NCT05961137 Completed - Sepsis Clinical Trials

Orange Park Out-of-Hospital Quality Improvement Study for Improving CMS Sepsis Core Measures

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

The goal of this quality improvement study is to measure the impact of incorporation of a manual rapid fluid infuser (RFI) for intravenous crystalloid infusion in patients with suspected sepsis in the prehospital interval. The main question[s] it aims to answer are: - Does the intervention affect the timeliness of fluid administration? - Does the intervention affect CMS sepsis bundle care measure compliance? - Does the intervention affect processes and outcomes of care? - Are there any adverse effects? Researchers will compare this intervention to use of more conventional gravity or pressure-infusion bag crystalloid infusion.

NCT ID: NCT05953441 Completed - Sepsis Clinical Trials

Artificial Intelligence Versus Human-controlled Doctor in Virtual Reality Simulation for Sepsis Team Training

Start date: August 8, 2022
Phase: N/A
Study type: Interventional

The purpose of the study is to compare the effectiveness of Artificial Intelligence virtual doctor with human-controlled virtual doctor avatars on nursing students' sepsis care and interprofessional communication.

NCT ID: NCT05909384 Completed - Sepsis Clinical Trials

Management of Sepsis in Resource Limited Settings Using a Delphi Method.

Start date: May 16, 2023
Phase:
Study type: Observational

Rapid evolution of sepsis syndromes means that timely diagnosis and treatment are critical in improving outcomes but this may be difficult to achieve in many low- and middle- income countries (LMICs) and there is a lack of high quality clinical evidence to guide diagnosis and management in LMIC settings. The wide variability in health systems in LMICs means that additional areas of guidance may be required where staff or facilities are lacking. In the absence of clinical data, to address some of these issues, the investigators aim to use Delphi methodology to obtain experts consensus statements on some specific aspects of sepsis management in LMICs.

NCT ID: NCT05774054 Completed - Sepsis Clinical Trials

The Impact of Early Norepinephrine Administration on Outcomes of Patients With Sepsis-induced Hypotension

Start date: May 1, 2021
Phase: N/A
Study type: Interventional

Septic shock is defined as sepsis with persistent hypotension requiring vasopressors to maintain mean arterial pressure (MAP)≥ 65 mmHg and a serum lactate level of > 2 mmol/L (18 mg/dL) despite sufficient volume resuscitation . Hypovolemia (both relative and absolute) and reduced vascular tone have a role in determining the severity of hypotension in septic shock

NCT ID: NCT05727293 Completed - Sepsis Bacterial Clinical Trials

A Case Report of a Patient With Intellectual Disability and Neurogenic Bladder Complicated With Sepsis

Start date: September 6, 2022
Phase:
Study type: Observational

A case report of a patient with intellectual disability and neurogenic bladder complicated with sepsis

NCT ID: NCT05684133 Completed - Sepsis Clinical Trials

REMISE Study: REMnant Biospecimen Investigation in SEpsis

REMISE
Start date: October 25, 2022
Phase:
Study type: Observational

In the REMISE is study, we will compare blood proteins, biomarkers, and other -omics prospectively collected from patients with sepsis from two sources, i.) remnant (discarded) samples from the clinical laboratory, and ii.) prospectively collected in UPMC Presbyterian hospital research coordinator specimen collected biospecimens. Analyses will include traditional biomarkers, quantitative proteomics, metabolomics, lipidomics, transcriptomics, and pathogen genomic sequencing in both sets of samples. This data will allow the assessment of the feasibility, integrity, and scientific value of remnant samples compared to research coordinator samples collected at the bedside for mechanistic sepsis research.